文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

茶碱作为吸入性糖皮质激素辅助治疗对COPD急性加重的影响:一项随机临床试验

Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

TWICS试验为实用型双盲安慰剂对照随机试验,纳入1578例既往一年至少2次急性加重且使用吸入性糖皮质激素的COPD患者,比较低剂量茶碱(血浆浓度1-5 mg/L)与安慰剂。结果显示,治疗1年内茶碱组与安慰剂组中重度急性加重率无显著差异(调整后IRR 0.99,95%CI 0.91-1.08),不支持低剂量茶碱作为吸入性糖皮质激素的辅助治疗来预防COPD急性加重。

要点

  • 对于高急性加重风险的COPD患者,低剂量茶碱未减少1年内急性加重次数。
  • 茶碱组恶心(10.9% vs 7.9%)和头痛(9.0% vs 7.9%)发生率略高。
  • 本研究不支持在吸入性糖皮质激素基础上加用低剂量茶碱预防急性加重。

核心结论

  • 在因COPD高急性加重风险而使用吸入性糖皮质激素的成人中,加用低剂量茶碱与安慰剂相比未减少1年内急性加重次数。
  • 研究结果不支持低剂量茶碱作为吸入性糖皮质激素的辅助治疗用于预防COPD急性加重。

研究设计与样本

  • TWICS试验为实用型、双盲、安慰剂对照、随机临床试验,2014年2月6日至2016年8月31日入组,末次随访至2017年8月31日。
  • 纳入FEV1/FVC<0.7且既往一年至少2次需抗生素和/或口服糖皮质激素治疗的急性加重、并使用吸入性糖皮质激素的COPD患者。
  • 共纳入英国121个初级和二级医疗中心的1578例参与者,随机接受低剂量茶碱(根据理想体重和吸烟状态调整,200 mg每日一次或两次,使血浆浓度达1-5 mg/L,n=791)或安慰剂(n=787)。

主要发现

  • 共1567例参与者纳入分析,平均(SD)年龄68.4(8.4)岁,54%(843)为男性。
  • 主要结局可评估数据来自1536例参与者(98%)(茶碱组772例,安慰剂组764例)。
  • 共发生3430次急性加重:茶碱组1727次(平均每年2.24次,95%CI 2.10-2.38),安慰剂组1703次(平均每年2.23次,95%CI 2.09-2.37);未调整平均差0.01(95%CI -0.19至0.21),调整后发生率比0.99(95%CI 0.91-1.08)。
  • 严重不良事件:心脏事件茶碱组2.4% vs 安慰剂组3.4%;胃肠道事件2.7% vs 1.3%;不良反应如恶心(10.9% vs 7.9%)和头痛(9.0% vs 7.9%)。

关键数值与推荐

  • 主要结局为1年治疗期间参与者报告的需要抗生素和/或口服糖皮质激素治疗的中度或重度急性加重次数。
  • 茶碱剂量根据理想体重和吸烟状态调整,目标血浆浓度为1-5 mg/L。

临床怎么用

  • 对于使用吸入性糖皮质激素预防急性加重的COPD患者,不应常规加用低剂量茶碱。
  • 临床医生应基于现有证据选择其他有明确获益的预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic obstructive pulmonary disease (COPD) is a major global health issue and theophylline is used extensively. Preclinical investigations have demonstrated that low plasma concentrations (1-5 mg/L) of theophylline enhance antiinflammatory effects of corticosteroids in COPD. OBJECTIVE: To investigate the effectiveness of adding low-dose theophylline to inhaled corticosteroids in COPD. DESIGN, SETTING, AND PARTICIPANTS: The TWICS (theophylline with inhaled corticosteroids) trial was a pragmatic, double-blind, placebo-controlled, randomized clinical trial that enrolled patients with COPD between February 6, 2014, and August 31, 2016. Final follow-up ended on August 31, 2017. Participants had a ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC) of less than 0.7 with at least 2 exacerbations (treated with antibiotics, oral corticosteroids, or both) in the previous year and were using an inhaled corticosteroid. This study included 1578 participants in 121 UK primary and secondary care sites. INTERVENTIONS: Participants were randomized to receive low-dose theophylline (200 mg once or twice per day) to provide plasma concentrations of 1 to 5 mg/L (determined by ideal body weight and smoking status) (n = 791) or placebo (n = 787). MAIN OUTCOMES AND MEASURES: The number of participant-reported moderate or severe exacerbations treated with antibiotics, oral corticosteroids, or both over the 1-year treatment period. RESULTS: Of the 1567 participants analyzed, mean (SD) age was 68.4 (8.4) years and 54% (843) were men. Data for evaluation of the primary outcome were available for 1536 participants (98%) (772 in the theophylline group; 764 in the placebo group). In total, there were 3430 exacerbations: 1727 in the theophylline group (mean, 2.24 [95% CI, 2.10-2.38] exacerbations per year) vs 1703 in the placebo group (mean, 2.23 [95% CI, 2.09-2.37] exacerbations per year); unadjusted mean difference, 0.01 (95% CI, -0.19 to 0.21) and adjusted incidence rate ratio, 0.99 (95% CI, 0.91-1.08). Serious adverse events in the theophylline and placebo groups included cardiac, 2.4% vs 3.4%; gastrointestinal, 2.7% vs 1.3%; and adverse reactions such as nausea (10.9% vs 7.9%) and headaches (9.0% vs 7.9%). CONCLUSIONS AND RELEVANCE: Among adults with COPD at high risk of exacerbation treated with inhaled corticosteroids, the addition of low-dose theophylline, compared with placebo, did not reduce the number COPD exacerbations over a 1-year period. The findings do not support the use of low-dose theophylline as adjunctive therapy to inhaled corticosteroids for the prevention of COPD exacerbations. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN27066620.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Devereux G, Cotton S, Fielding S, et al. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. JAMA. 2018. PMID: 30326124. doi:10.1001/jama.2018.14432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。